Innoviva
Innoviva Inc is an American biopharmaceutical asset management and royalty holding company focused on respiratory and infectious disease therapies. The company holds royalty rights to bio-pharmaceutical products developed in partnership with GSK, including Trelegy Ellipta and Relvar/Breo Ellipta, alongside operating clinical specialty pharmaceutical subsidiaries. Revenue is primarily generated from recurring royalty cash flows based on global product sales of GSK-marketed respiratory inhalers alongside commercial sales of hospital infectious disease drugs like Xacduro and Giapreza. Core end markets serve pulmonology clinics, hospital intensive care units, infectious disease practices, and prescription patients globally. Innoviva holds a market-leading position as a specialized biopharmaceutical royalty holder with significant cash flow generation from respiratory franchises. The corporation is headquartered in Burlingame, California, and its common stock trades on the Nasdaq Global Select Market.
4 of the funds FundTelligence covers report a position in Innoviva.
- Legal name
- INNOVIVA
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Innoviva
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.39 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.09 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)